Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
larger decrease » marked decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
larger decrease » marked decrease (Expand Search)
-
1721
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1722
-
1723
-
1724
-
1725
-
1726
-
1727
-
1728
-
1729
-
1730
-
1731
-
1732
-
1733
-
1734
-
1735
-
1736
-
1737
-
1738
-
1739
-
1740